Nikoletta Mili

Nikoletta Mili

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2021 in Endocrine
Verified
Journal Article
Closed access
PDF file
NMNikoletta Mili
Nikoletta Mili
SPStavroula A. Paschou
Stavroula A. Paschou
DGDimitrios G. Goulis
Dimitrios G. Goulis
MDMeletios-Athanasios Dimopoulos
Meletios-Athanasios Dimopoulos
ILIrene Lambrinoudaki
Irene Lambrinoudaki
TPTheodora Psaltopoulou
Theodora Psaltopoulou

15 March 2021 in Menopause
Verified
Journal Article
Closed access
NMNikoletta Mili
Nikoletta Mili
SPStavroula A. Paschou
Stavroula A. Paschou
AAAnastasia Armeni
Anastasia Armeni
NGNeoklis Georgopoulos
Neoklis Georgopoulos
DGDimitrios G. Goulis
Dimitrios G. Goulis
ILIrene Lambrinoudaki
Irene Lambrinoudaki
Importance: Genitourinary syndrome of menopause (GSM) consists of genitourinary tract symptoms that occur due to physical changes caused by estrogen concentrations decline after menopause. Unlike menopausal symptoms, which subside with time, GSM symptoms persist throughout a woman's life. Objective: This article aimed to systematically review the literature to investigate the prevalence of GSM and its treatment. Evidence Review: The search was conducted in the electronic databases PubMed, CENTRAL, and EMBASE until October 2020. Eligible for the systematic review were studies and surveys conducted via questionnaires or medical interviews evaluating the existence of GSM symptoms with or without gynecological examination in postmenopausal women or women >40 years of age. Findings: After the application of predefined inclusion/exclusion criteria, 27 studies were included in the systematic review. The prevalence of GSM-related symptoms, such as vaginal dryness, irritation, itching, and dyspareunia, ranged from 13% to 87%. The use of GSM-specific treatment varied from 13% to 78%. Over-the-counter lubricants and moisturizers were the most popular therapeutic options (24.0%-85.5%), followed by low-dose vaginal estrogens (4.8%-35.0%). Vaginal health is not frequently discussed during doctor visits and awareness about the condition and the number of treatment options is low. Women are concerned about the long-term safety and side effects of hormonal treatment. The majority of women who suffer from genitourinary symptoms are dissatisfied by the treatment they have used. Conclusions and Relevance: GSM is a highly prevalent condition among women. Nevertheless, women are frequently not aware of its cause and its treatment options. The findings of this review underline the need for education of patients and healthcare professionals regarding GSM diagnosis and treatment options. Video Summary: http://links.lww.com/MENO/A720.

3 November 2022 in Endocrine
Verified
Journal Article
Open access
PDF file
SPStavroula A. Paschou
Stavroula A. Paschou
EBEvanthia Bletsa
Evanthia Bletsa
MPMaria Papazisi
Maria Papazisi
NMNikoletta Mili
Nikoletta Mili
FKFotini Kanouta
Fotini Kanouta
ILIrene Lambrinoudaki
Irene Lambrinoudaki
Endocrinopathies during pregnancy constitute a challenging issue, being prevalent and requiring appropriate management to avoid maternal and fetal complications. This review aims to summarize and present major endocrine problems during pregnancy, the appropriate screening, maternal monitoring and management, fetal monitoring, and follow-up. Glucose metabolism, thyroid function, as well as calcium and vitamin D metabolism are the main endocrine domains that should be screened and monitored during pregnancy. Gestational diabetes mellitus (GDM) is the most prevalent endocrine disease during pregnancy, followed by thyroid disorders. Specific recommendations are provided for the optimal clinical care of pregnant women and their offspring for GDM, thyroid disorders, and calcium and vitamin D disorders.

5 August 2022 in Current Opinion in Endocrine and Metabolic Research
Verified
Journal Article
Closed access
EAEleni Armeni
Eleni Armeni
NMNikoletta Mili
Nikoletta Mili
ESElina Siliogka
Elina Siliogka
DGDimitrios G. Goulis
Dimitrios G. Goulis
ILIrene Lambrinoudaki
Irene Lambrinoudaki

19 May 2023 in Geriatrics
Verified
Journal Article
Open access
PDF file
ECEfstathia Chatziandreou
Efstathia Chatziandreou
AEAndreas Eustathiou
Andreas Eustathiou
AAAreti Augoulea
Areti Augoulea
EAEleni Armeni
Eleni Armeni
NMNikoletta Mili
Nikoletta Mili
KSKalantaridou N Sophia
Kalantaridou N Sophia
This study aimed to assess an eligible cut-off value of anti-Müllerian hormone (AMH) to detect ovarian senescence in a group of premenopausal Greek women to evaluate the possible link between AMH-values and the severity of climacteric symptoms during a follow-up of 24 months. This study included 180 women (group A, 96 women of late reproductive stage/early perimenopause; group B, 84 women in late perimenopause). We measured AMH blood levels and assessed climacteric symptoms using the Greene scale. Log-AMH is inversely associated with postmenopausal status. The AMH cut-off of 0.012 ng/mL predicts the postmenopausal status with a sensitivity of 24.2% and specificity of 30.5%. The postmenopausal stage associated with age (OR = 1.320, 95%CI: 1.084–1.320) and AMH (values ≥ vs. <0.012 ng/mL, OR = 0.225, 95%CI: 0.098–0.529, p-value < 0.001). Moreover, the severity of vasomotor symptoms (VMS) was only associated inversely with AMH (b-coefficient = −0.272, p-value = 0.027). In conclusion, AMH levels measured in the late premenopausal period are inversely associated with the time to ovarian senescence. In contrast, AMH levels measured in the perimenopausal period are inversely associated only with the severity of VMS. Therefore, a cut-off of 0.012 ng/mL predicts menopause with low sensitivity and specificity, making it challenging to use in a clinical setting.

31 January 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
SPStavroula A. Paschou
Stavroula A. Paschou
AAAngeliki Andrikopoulou
Angeliki Andrikopoulou
NMNikoletta Mili
Nikoletta Mili
ASANNA SVARNA
ANNA SVARNA
MKMaria Kaparelou
Maria Kaparelou
MLMichalis Liontos
Michalis Liontos
Background/Objectives: Survival rates for ovarian cancer remain distressingly low. Despite established prognostic factors, the need to identify modifiable parameters to influence survival outcomes is imperative. Overweight and obesity, both prevalent conditions, have been implicated in cancer development and potentially poor survival. However, conflicting data on the associations of body mass index (BMI) with progression-free survival (PFS) and overall survival (OS) in ovarian cancer patients necessitate further exploration. This study aims to investigate the prognostic role of BMI before chemotherapy in women with ovarian cancer, specifically focusing on PFS and OS. Methods: A retrospective analysis encompassed 1,136 patients diagnosed with ovarian carcinomas between 1995 and 2018. Patients were categorized based on BMI at presentation, and a comprehensive examination of clinicopathological, treatment, and survival data was conducted. Results: In the patient population, normal weight patients (BMI < 25 kg/m2) demonstrated a median PFS of 12.8 months (95% CI 11.7–13.9 months), while overweight/obese patients (BMI ≥ 25 kg/m2) exhibited a significantly longer median PFS of 14.9 months (95% CI 13.6–16.4 months, P = 0.006). No statistically significant difference was noted in median OS between the two BMI groups. Subgroup analysis for different histological subtypes revealed a statistically significant benefit for overweight and obese patients with serous and endometrioid histology (mPFS 12.9 months, 95% CI 11.7–14.0 vs. 15.6 months, 95% CI 13.9–17.3, P = 0.012 and 14.6 months 95% CI 13.7–15.5 vs. 25.6 months, 95% CI 9.5–41.7, P = 0.031, respectively). Additionally, BMI ≥ 25 kg/m2 demonstrated a significant advantage in advanced-stage disease. Conclusions: The study underscores the intricate association between BMI and ovarian cancer prognosis. While a statistically significant difference in progression-free survival was noted between normal weight and overweight/obese patients, with the latter group experiencing a survival benefit, no such difference was observed in overall survival.